Suchergebnisse - "Curtin, Nicola"

PubPharm (7)

1

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

enthalten in: Cancer medicine | 2018

von Franklin, M. | Gentles, L. | Matheson, E. | +10

2

The Use of PARP Inhibitors in Cancer Therapy : Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Shall, S. | Gaymes, T. | Farzaneh, F. | +2

3

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

4

PARP inhibitors for cancer therapy

Erschienen: [S.l.], Humana Press, 2015

Cancer drug discovery and development - Vol. 83

von Curtin, N.

5

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

6

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

7

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

1
[1]